and consultants of the Company and (ii) a decrease in other expenses of $68,626 primarily related to lower insurance costs and travel

filing / Aug 14, 2026 / receipt

of $72,588 primarily related to lower insurance costs and travel costs in the current period. These amounts were partially offset by a

filing / Aug 14, 2026 / receipt

an increase in personnel and consulting expenses of $525,719 primarily due to increased headcount, an increase in medical and regulatory

filing / Aug 14, 2026 / receipt

Company rented office space on a month-to-month basis with no long-term commitment, representing a short-term lease. As a result,

filing / Aug 14, 2026 / receipt

the Company has elected to apply the short-term lease exemption to its office lease and therefore has not recorded a right of use

filing / Aug 14, 2026 / receipt

board of director fees, investor and public relations, and travel expenses. We anticipate our general and administrative expenses will increase in the future as we expand our operations, including increasing our headcount to support our continued research and development activities and preparing for later-stage clinical studies and potential commercialization of elraglusib.

filing / May 14, 2026 / receipt

expenses of $352,518 primarily due to increased headcount combined with an increase in medical and regulatory consulting associated with

filing / May 14, 2026 / receipt

rented office space on a month-to-month basis with no long-term commitment, representing a short-term lease. As a result, the Company

filing / May 14, 2026 / receipt

has elected to apply the short-term lease exemption to its office lease and therefore has not recorded a right of use (“ROU”)

filing / May 14, 2026 / receipt